UCB’s zilucoplan for treating gMG is among the latest new drugs that the European Medicines Agency has started reviewing for potential EU marketing approval.
Zilucoplan, UCB’s investigational treatment for generalized myasthenia gravis (gMG) in adults, is among the latest drugs that the European Medicines Agency has added to its list of products under review for potential pan-EU marketing authorization.
Zilucoplan, which is not yet authorized anywhere in the world, is a once-daily self-administered subcutaneous peptide inhibitor of complement component 5 (C5 inhibitor)
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.
The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.
